nature portfolio

corresponding author(s):	Prof. Christian Luscher
Last updated by author(s):	Apr 2, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics	
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed	
The exact sam	nple size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical Only common to	test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section.
A description	of all covariates tested
A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full descript AND variation	ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypot	thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted is exact values whenever suitable.
For Bayesian a	analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchic	al and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of e	effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
·	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and c	code
Policy information abou	ut <u>availability of computer code</u>
Data collection ME	ED-PC IV 4.34 (Operant Behaviour), TDT synapse version 84 Tucker-Davis (Photometry)
Data analysis MS	S-Excel 16 16.0.5, GraphPad Prism 10.0.2, Matlab R2019b, ImageJ 1.52n.
	com algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and urage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our $\underline{\text{policy}}$

Upon publication the raw data and custom matlab code will be available at zenodo (10.5281/zenodo.10890957)

		vith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> thnicity and racism.
Reporting on sex		Not applicable
Reporting on rac other socially rel groupings		Not applicable
Population chara	acteristics	Not applicable
Recruitment		Not applicable
Ethics oversight		Not applicable
ote that full informa	ation on the appro	oval of the study protocol must also be provided in the manuscript.
_		ehavioural & social sciences
or a reference copy of	the document with a	
or a reference copy of	the document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
or a reference copy of ife scier	nces stu	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
or a reference copy of	the document with an	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf Idy design points even when the disclosure is negative.
or a reference copy of ife scier Il studies must dis Sample size	nces stusces on these Sample size were For fiberphoton A details experi	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf Lidy design points even when the disclosure is negative. re estimated with a power calculation software (G*Power)
or a reference copy of ife scier All studies must dis Sample size Data exclusions	nces stusces on these Sample size were For fiberphoton A details experiwere replicated	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf Lidy design points even when the disclosure is negative. The estimated with a power calculation software (G*Power) The entry, conditional knock-down and optogenetic: animals where injection and/or fiber implantation were not correct The entry provided to facilitate replication by others. Behavior, fiberphotometry, staining and genetic experiment
Life scier All studies must dis Sample size Data exclusions Replication	nces stusces on these Sample size were For fiberphoton A details experi were replicated Mice were rand Cell counting (c	points even when the disclosure is negative. re estimated with a power calculation software (G*Power) metry, conditional knock-down and optogenetic: animals where injection and/or fiber implantation were not correct mental protocol is provided to facilitate replication by others. Behavior, fiberphotometry, staining and genetic experiment in at least 2 or more cohort, by two experimentater when possible. comply assigned to treatments condition. Treatment condition were randomized for occlusion experiment. Fos) was conducted by an experimenter blind to treatment. Fiber photometry and behavior experiments were realized fapplicable, but the experimentalist are always aware of the conditions. In situ hybridization for validation of th KD were

Materials & experimental systems	Methods
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and archaeology	MRI-based neuroimaging
Animals and other organisms	·
Clinical data	
Dual use research of concern	
·	

Antibodies

Antibodies used

Rabbit polyclonal anti c-Fos synaoptic system 226003; Goat anti-rabbit IgG alexa 488 invitrogen A1108, rabbit polyclonal anti-GFP

invitrogen A11122 Antibodies used

Validation

Laboratory animals

All primary antibody were suitable for IHC according to the vendor. Anti c-Fos antibody show perfect results in immunostaining experiment like ICC, IHC and IHC-P according to the manufacturer's website. Furthermore, it has been validated in more than 15 publications based on the manifacturer website. Anti-GFP antibody stained selectively in virus infected area in our hand, and was validated more than a 1000 time according to the manufacturer's website.

C57BL/6J, DAT-IRES-Cre (B6.SJL-Slc6a3tm1.1(cre)Bkmn/J), GAD-Cre (Gad2tm2(cre)Z), µOR fl/fl (B6;129-Oprm1tm1.1Cgrf/KffJ), µOR

Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

cre/cre (B6N-Oprm1tmT2A-eGFP/Cre(ICS)/Kf) and SST-IRES-cre (SSTtm2.1(cre)Zjh/J) mice lines were used. For all strains, mice ages 10-22 week were used for the experiments.

Wild animals No wild animals were used in the study

For all strain, both male and female mice were use, but if not possible it was stated in the materials and methods. Reporting on sex

No fields collected samples were used in the study. Field-collected samples

All procedures were approved by the institutional animal Care and use committee of the university of Geneva and by the animal Ethics oversight

welfare committe of the Canton of Geneva, in accordance with the swiss law

Note that full information on the approval of the study protocol must also be provided in the manuscript.